These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20446917)

  • 1. siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors.
    Haouala A; Rumpold H; Untergasser G; Buclin T; Ris HB; Widmer N; Decosterd LA
    Drug Metab Lett; 2010 Apr; 4(2):114-9. PubMed ID: 20446917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
    D'Cunha R; Bae S; Murry DJ; An G
    Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.
    Harmsen S; Meijerman I; Maas-Bakker RF; Beijnen JH; Schellens JH
    Eur J Pharm Sci; 2013 Mar; 48(4-5):644-9. PubMed ID: 23277288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line.
    Harmsen S; Meijerman I; Febus CL; Maas-Bakker RF; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):765-71. PubMed ID: 20041327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
    Azzariti A; Porcelli L; Simone GM; Quatrale AE; Colabufo NA; Berardi F; Perrone R; Zucchetti M; D'Incalci M; Xu JM; Paradiso A
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):335-46. PubMed ID: 19495754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
    Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
    Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular Doppler Spectroscopy detects altered drug response in SKOV3 tumor spheroids with silenced or inhibited P-glycoprotein.
    Narayanan G; Merrill D; An R; Nolte DD; Turek JJ
    Biochem Biophys Res Commun; 2019 Jul; 514(4):1154-1159. PubMed ID: 31103263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif.
    Ye S; MacEachran DP; Hamilton JW; O'Toole GA; Stanton BA
    Am J Physiol Cell Physiol; 2008 Sep; 295(3):C807-18. PubMed ID: 18650266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression.
    Maitra R; Halpin PA; Karlson KH; Page RL; Paik DY; Leavitt MO; Moyer BD; Stanton BA; Hamilton JW
    Biochem J; 2001 May; 355(Pt 3):617-24. PubMed ID: 11311122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction.
    Fleisher B; Unum J; Shao J; An G
    J Pharm Sci; 2015 Jan; 104(1):266-75. PubMed ID: 25418056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration.
    Yamagishi T; Sahni S; Sharp DM; Arvind A; Jansson PJ; Richardson DR
    J Biol Chem; 2013 Nov; 288(44):31761-71. PubMed ID: 24062304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
    Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between functional and molecular analysis of mdr1 P-glycoprotein in human solid-tumor xenografts.
    Broxterman HJ; Feller N; Kuiper CM; Boven E; Versantvoort CH; Teerlink T; Pinedo HM; Lankelma J
    Int J Cancer; 1995 Jun; 61(6):880-6. PubMed ID: 7790125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug resistance: molecular mechanisms and clinical relevance.
    Ling V
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the pharmacokinetics and cardiotoxicity of doxorubicin in rat receiving nilotinib.
    Zhou ZY; Wan LL; Yang QJ; Han YL; Li Y; Yu Q; Guo C; Li X
    Toxicol Appl Pharmacol; 2013 Oct; 272(1):238-44. PubMed ID: 23770382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells.
    Gupta SV; Sass EJ; Davis ME; Edwards RB; Lozanski G; Heerema NA; Lehman A; Zhang X; Jarjoura D; Byrd JC; Pan L; Chan KK; Kinghorn AD; Phelps MA; Grever MR; Lucas DM
    AAPS J; 2011 Sep; 13(3):357-64. PubMed ID: 21538216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors.
    Shao J; Markowitz JS; Bei D; An G
    J Pharm Sci; 2014 Dec; 103(12):3810-3833. PubMed ID: 25308414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
    Barrand MA; Bagrij T; Neo SY
    Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PKC-independent modulation of multidrug resistance in cells with mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin 1.
    Spitaler M; Utz I; Hilbe W; Hofmann J; Grunicke HH
    Biochem Pharmacol; 1998 Oct; 56(7):861-9. PubMed ID: 9774148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment.
    Fardel O; Lecureur V; Daval S; Corlu A; Guillouzo A
    Eur J Biochem; 1997 May; 246(1):186-92. PubMed ID: 9210482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.